Navigation Links
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
Date:8/5/2008

0,

-------- --------

2008 2007 2008 2007

---- ---- ---- ----

Nexavar product revenue, net (as

recorded by Bayer) $168,520 $81,332 $320,416 $142,212

Revenue subject to profit sharing

(as recorded by Bayer) 156,547 81,332 308,443 142,212

Combined cost of goods sold,

distributed, selling, general and

administrative expenses 80,135 49,285 142,838 85,734

Combined research and development

expenses 43,946 34,856 81,424 68,146

------- ------- ------- -------

Combined collaboration profit

(loss) $32,466 $(2,809) $84,181 $(11,668)

------- -------- ------- ---------

Onyx's share of collaboration

profit (loss) $16,233 $(1,405) $42,091 $(5,834)

Reimbursement of Onyx's direct

development and marketing expenses 13,128 8,875 25,008 16,329

Royalty revenue 838 - 838 -

------ ------ ------ ------

Onyx net revenue from

unconsolidated joint business $30,199 $7,470 $67,937 $10,495

------- ------ ------- -------

ONYX PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

(In thousands)

Jun. 30, Dec. 31,

2008 2007

(unaudited)
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... Market Research, "Biological Drugs Market - Global Industry Analysis, ... the global biological drugs market is estimated at USD ... at a CAGR of 10.1% from 2014 to 2020, ... in 2020. , The biological drugs market is witnessing ...
(Date:7/25/2014)... PA (PRWEB) July 25, 2014 The ... Call for Topics for Conferee Networking. These two-hour sessions ... interests to meet and resolve problems, discuss new techniques, ... The deadline to submit a topic for consideration is ... pittcon.org . The Conferee Networking committee will review ...
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2
... de Heer, professor of physics at the Georgia Institute of ... Boston today. De Heer was cited by the society for ... graphene." The MRS Medal recognizes an exceptional achievement in materials ... awarded for a specific outstanding recent discovery or advancement that ...
... (DARPA) has awarded the UCLA Henry Samueli School of ... research on a technology known as non-volatile logic, which ... even while powered off, then start up and run ... broad implications across a range of technologies, including portable ...
... Dec. 2, 2010 Physicians at Thomas Jefferson University ... the potential for fully automated interpretation of coronary CT ... rule out coronary artery disease (CAD) in the major ... was presented in Chicago at the Radiological Society of ...
Cached Biology Technology:Georgia Tech's Walt de Heer awarded Materials Research Society Medal 2UCLA receives $8.4 million to lead research on ultra-low-power, non-volatile logic technologies 2Rcadia COR Analyzer System Safely Rules Out Coronary Artery Disease in Main Coronary Arteries and Branch Vessels 2
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
(Date:7/25/2014)... for Medical Research have identified the functions of ... to triggering the mating process in mice. , They ... detect pheromones that indicate when a female is present. ... the female mouse is ovulating and ready to mate. ... Stowers, researchers believe mice developed this system through evolution ...
(Date:7/25/2014)... , July 25, 2014 Biometrics ... are turning to digital technology for online & commerce ... Google Inc. (NASDAQ: GOOG ), LifeLock Inc. ... V ), Apple Inc. (NASDAQ: AAPL ... Inc., (OTCQB: NXTD) a biometric authentication company focused on ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... Osteoporosis Foundation (IOF) has issued a literature review ... safety of two minimally invasive techniques for vertebral ... kyphoplasty (BKP). The review also lists important recommendations ... highlights research questions still unresolved. Vertebral fractures, ...
... availability of the newest edition of its authoritative reference ... 10th edition, is available in both print and, for ... edition of the Manual of Clinical Microbiology marks a ... says Editor-in-Chief James Versalovic of Texas Children,s Hospital. "For ...
... found that the risk of death and cardiovascular disease, ... intense or conventional. They did find, however, that when ... intensive level, the chance of damaging small blood vessels ... eyes and kidneys, is reduced. But aiming for this ...
Cached Biology News:IOF urges systematic osteoporosis management after vertebral fracture augmentation 2New edition of Manual of Clinical Microbiology offers digital access 2Type 2 diabetes: 'Intensive' versus 'conventional' blood glucose control -- no clear picture 2
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
...
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Biology Products: